Rafabegron

Drug Profile

Rafabegron

Alternative Names: AD-9677; AJ-9677; TAK-677

Latest Information Update: 30 Sep 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Pharmaceutical
  • Developer Dainippon Pharmaceutical; Takeda Pharmaceuticals North America
  • Class Acetic acids; Antihyperglycaemics; Indoles; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 30 Sep 2003 Discontinued - Phase-II for Obesity in USA (unspecified route)
  • 30 Sep 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (PO)
  • 30 Sep 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top